Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536342 | 1.00 | RAB9A (0.49) | RAB9ASMN1; SMN2NPC1MAPTALOX12 | |
| SCHEMBL3545278 | 0.87 | PHGDH (0.52) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL2762764 | 0.77 | BCHE (0.43) | SMN1; SMN2FKBP1AGAAKMT2AALDH1A1 | |
| SCHEMBL11711031 | 0.75 | RAB9A (0.54) | RAB9ASMN1; SMN2NPC1MAPTALOX12 | |
| SCHEMBL3609711 | 0.71 | SMN1; SMN2 (0.43) | RAB9ASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL28649066 | 0.69 | RAB9A (0.59) | RAB9ASMN1; SMN2NPC1HPGDPHGDH | |
| SCHEMBL946143 | 0.68 | HPGD (0.86) | SMN1; SMN2HPGDPHGDHTSHRGAA | |
| SCHEMBL8727982 | 0.68 | MGLL (0.59) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL5931233 | 0.67 | KMT2A (0.50) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL5931234 | 0.67 | KMT2A (0.50) | RAB9ASMN1; SMN2NPC1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | RAB9A 4426/4885SMN1; SMN2 4287/4885NPC1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.